Not provided
Not provided
Not provided
Not provided
Not provided
The associated funding source was ended, and the proposed duration of the study ended.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary goal of this project is to study the feasibility of a prototype brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of metabolism and perfusion in Covid-19 negative and positive/once positive subjects. This study serves as a pilot study for establishing an imaging protocol for combined PET and MR derived functional information as well as MRI acquired anatomical information.
This study is a non-randomized non-treatment study. The intention of this work is an assessment of the PET insert technology, and not, for example, to perform a treatment assessment or drug assessment. This work will actively recruit 10 individuals (5 Covid-19 negative and 5 Covid-19 previously positive in the last 180 days) to perform imaging of the brain with an FDA-approved radiotracer.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Covid-19 Negative/Uninfected Population | Experimental | 5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert. |
|
| Covid-19 Positive/Infected Population | Experimental | 5 participants will be recruited, injected with radiopharmaceutical, and imaged on the 3T PETMR with PET insert. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Injected radiotracer with PET Insert | Diagnostic Test |
|
| Measure | Description | Time Frame |
|---|---|---|
| Image quality of PET/MR | The key specific measurement is that resulting PET/MR images are of high quality, with comparable or better resolution and noise than that seen in other published articles. | Up to 24 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Craig Levin, M. Phil., PhD. | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94305 | United States |
Not provided
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D012141 |
| Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |